Cresco Labs (CRLBF) Total Current Liabilities (2019 - 2026)
Cresco Labs (CRLBF) posted Total Current Liabilities of $98.2 million for Q1 2026, down 2.0% on a QoQ basis from $100.2 million in Q4 2025, and down 13.27% year-over-year from $113.2 million in Q1 2025.
Cresco Labs (CRLBF) Total Current Liabilities (2019 - 2026) Analysis & Trends
Cresco Labs' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $98.2 million for Q1 2026.
- Quarterly Total Current Liabilities fell 13.27% year-over-year to $98.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $98.2 million (down 13.27% YoY) and the FY2025 annual result came in at $100.2 million, up 6.19% from the prior year.
- Total Current Liabilities was $98.2 million for Q1 2026 at Cresco Labs, down from $100.2 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $331.2 million in Q1 2022 and bottomed at $94.3 million in Q4 2024.
- A 5-year average of $186.3 million and a median of $200.2 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities increased 29.31% — and 2024, when it tumbled 52.89%.
- Cresco Labs' Total Current Liabilities stood at $255.9 million in 2022, then decreased by 21.74% to $200.2 million in 2023, then tumbled by 52.89% to $94.3 million in 2024, then increased by 6.19% to $100.2 million in 2025, then declined by 2.0% to $98.2 million in 2026.
- Business Quant data shows CRLBF's Total Current Liabilities at $98.2 million in Q1 2026, $100.2 million in Q4 2025, and $97.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 6.56 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.53 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 18.06 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 6.81 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 831.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.66 Bn |
| 10 | Cresco Labs | 254.96 Mn | 99.57 Mn | 75.45 Mn | 98.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 98.17 Mn |
| Dec 31, 2025 | 100.18 Mn |
| Sep 30, 2025 | 97.37 Mn |
| Jun 30, 2025 | 101.32 Mn |
| Mar 31, 2025 | 113.20 Mn |
| Dec 31, 2024 | 94.34 Mn |
| Sep 30, 2024 | 158.57 Mn |
| Jun 30, 2024 | 136.88 Mn |
| Mar 31, 2024 | 209.15 Mn |
| Dec 31, 2023 | 200.24 Mn |
| Sep 30, 2023 | 260.88 Mn |
| Jun 30, 2023 | 237.65 Mn |
| Mar 31, 2023 | 272.55 Mn |
| Dec 31, 2022 | 255.87 Mn |
| Sep 30, 2022 | 270.56 Mn |
| Jun 30, 2022 | 228.22 Mn |
| Mar 31, 2022 | 331.19 Mn |
| Dec 31, 2021 | 288.39 Mn |
| Sep 30, 2021 | 209.24 Mn |
| Mar 31, 2021 | 276.61 Mn |